[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i)...

AARD : 6.88 (+0.88%)
Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD

San Diego, California--(Newsfile Corp. - August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or...

AARD : 6.88 (+0.88%)
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action

SAN FRANCISCO , Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. ( NASDAQ: AARD ) of a pending...

AARD : 6.88 (+0.88%)
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or...

AARD : 6.88 (+0.88%)
Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: ...

AARD : 6.88 (+0.88%)
Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Aardvark Therapeutics, Inc. (“Aardvark” or...

AARD : 6.88 (+0.88%)
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD

The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD ) violations of the federal...

AARD : 6.88 (+0.88%)
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the...

AARD : 6.88 (+0.88%)
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation

SAN DIEGO , Aug. 20, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2026, in the lawsuit that was filed for certain investors in Aardvark...

AARD : 6.88 (+0.88%)
AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt

A securities class action alleges Aardvark Therapeutics overstated ARD-101's safety profile; Wall Street price targets collapsed from as high as $29 to $7 after the Phase 3 HERO trial was paused...

AARD : 6.88 (+0.88%)

Barchart Exclusives

Treasuries Have Reclaimed the Yield Crown From Dividend Stocks. Here’s How Income Investors Can Adapt.
Treasuries have reclaimed the yield advantage, with fewer than 4% of S&P 500 stocks now yielding more than the 10-year Treasury (near 4.69%), compared with nearly 63% a decade ago. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.